GlassScriptPhysician profile
Edward B Gripon
NPI 1063411775
$6,198.99
in general payments reported to CMS, 2019-2025
30 companies · $237 in 2025
The $237 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $480 · 2020: $681 · 2021: $858 · 2022: $1,271 · 2023: $1,444 · 2024: $1,229 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,909.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,908.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,422.91 | 2021-2025 | |
| Lundbeck LLC | $442.94 | 2019-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $433.77 | 2021-2024 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $433.52 | 2019-2024 | Trintellix |
| Alkermes, INC. | $415.94 | 2022-2025 | Lybalvi, Aristada |
| Corium, LLC | $362.42 | 2021-2024 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $321.55 | 2019-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $276.18 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $248.52 | 2020-2024 | Austedo Xr |
| Allergan, INC. | $246.50 | 2019-2020 | |
| Tris Pharma INC | $228.27 | 2019-2024 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $223.49 | 2021-2024 | Qelbree |
| Vanda Pharmaceuticals INC. | $207.20 | 2020-2024 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $145.30 | 2019-2023 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $131.29 | 2019-2023 | Jornay Pm |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $114.14 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $90.16 | 2022 | |
| Axsome Therapeutics, INC. | $75.51 | 2022-2025 | Auvelity |
| Merck Sharp & Dohme LLC | $69.97 | 2021-2023 | Belsomra |
| Almatica Pharma LLC | $56.90 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $51.22 | 2023 | Quviviq |
| Neuronetics, INC. | $36.36 | 2019 | |
| Neos Therapeutics, LP | $35.75 | 2019-2020 | |
| Shire North American Group INC | $25.54 | 2019 | |
| Inspire Medical Systems, INC. | $22.57 | 2025 | Inspire |
| Adlon Therapeutics L.P. | $20.58 | 2020 | |
| Eisai INC. | $16.65 | 2020 | |
| Noven Therapeutics, LLC | $16.64 | 2020 | |
| Owp Pharmaceuticals, INC. | $16.17 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Gripon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.